PCF joins Exosome for biofluid molecular diagnostics technology clinical validation

17 October 2011 (Last Updated October 17th, 2011 18:30)

The Prostate Cancer Foundation (PCF) and Exosome Diagnostics have entered into a multiyear collaboration agreement to accelerate clinical validation of Exosome's biofluid molecular diagnostics technology in prostate cancer.

The Prostate Cancer Foundation (PCF) and Exosome Diagnostics have entered into a multiyear collaboration agreement to accelerate clinical validation of Exosome's biofluid molecular diagnostics technology in prostate cancer.

The collaboration will examine the capabilities of a new generation of RNA biofluid diagnostics for early identification, progression monitoring and advanced disease risk stratification in prostate cancer.

The aim of the project is to bring together clinicians, researchers and industry participants to explore and develop the full potential of stable, high quality disease-specific RNA, harvested from exosomes found in blood and urine samples.

The programme will support in-vitro diagnostic validation of known clinical prostate cancer biomarkers, as well as a robust biomarker discovery programme for prostate cancer from diagnosis through progression and treatment.

Exosome Diagnostics CEO James McCullough said the progressive collaboration assures they have the right people at the table on the front side of the clinical translation process to accurately assess unmet medical opportunities, properly design validation studies and deliver exosome technology benefits quickly to patients.

PCF chief science officer Howard Soule said they believe exosome technology may help improve diagnosis, therapy management and a reduction in patients suffering from prostate cancer.